Enzyme commercialization company Verenium Corp. (NASDAQ: VRNM) has announced the sale of several of its assets to Dutch firm DSM Food Specialties B.V., a business group of Royal DSM. The sale includes Verenium’s oilseed processing business, licenses for some enzymes aimed at the food and beverage market, and DSM will also get access to Vereniums gene libraries. Verenium will receive total compensation of $37 million.
Verenium’s big product was supposed to be an enzyme to speed up and maker cheaper the manufacture of cellulosic ethanol. Like other custom enzyme companies such as Codexis Inc. (NASDAQ: CDXS) and Solazyme Inc. (NASDAQ: SZYM), Verenium has had to turn to food and other products to make ends meet until the ethanol ship comes in.
Investors are very happy with the sale. Just before the market opens this morning, Verenium’s shares are up more than 36% at $4.20, which will be a new 52-week high if it holds.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
